Press releases
Press releases dating back to 2018 are available below. Search them by keyword or browse by year/business category.
Press releases for other local operating companies can be viewed on the local websites.
-
GSK’s ZEJULA is recommended for reimbursement by CADTH and INESSS for advanced ovarian cancer following response to first-line platinum-based chemotherapy
ZEJULA (niraparib) has received conditional positive recommendations for reimbursement
Read more -
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Medicago and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
Read more -
GSK named one of Canada’s Top 100 Employers in the year of the pandemic
GSK named one of Canada’s Top 100 Employers in the year of the pandemic
Read more -
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Medicago and GSK announce start of Phase 2/3 clinical trials of adjuvanted COVID-19 vaccine candidate
Read more -
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030
Read more -
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
New Study Concludes No Correlation Between NSAIDS — Including Ibuprofen — and Worsening COVID-19 Outcomes
Read more -
ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer
ZEJULA is approved in Canada for first-line maintenance treatment of women with advanced ovarian cancer
Read more -
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine
Read more -
GSK announces first participant vaccinated in Phase 3 Clinical Trials of its 5-in-1, Meningitis ABCWY vaccine candidate
GSK announces first participant vaccinated in Phase 3 Clinical Trials of its 5-in-1, Meningitis ABCWY vaccine candidate
Read more -
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
Read more -
Voluntary disclosure of payments to healthcare professionals in 2019
Voluntary disclosure of payments to healthcare professionals in 2019
Read more -
GSK steps up for COVID-19
GSK has been closely monitoring the COVID-19 pandemic and is supporting global efforts to tackle the virus.
Read more -
Save the Children Canada and GSK Address Mental Health Concerns of Children Affected by Cat Lake Crisis in Northern Ontario
Save the Children Canada and GSK Address Mental Health Concerns of Children Affected by Cat Lake Crisis in Northern Ontario
Read more -
GSK Canada statement on supply
GSK Canada statement on supply
Read more -
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Read more -
GSK Canada statement on COVID-19
GSK Canada statement on COVID-19
Read more -
Nucala is approved in Canada for use in adolescents and children aged 6 years and above with severe eosinophilic asthma
Nucala is approved in Canada for use in adolescents and children aged 6 years and above with severe eosinophilic asthma
Read more -
Bora Pharmaceuticals to Acquire GSK Mississauga-based Facility
Bora Pharmaceuticals to Acquire GSK Mississauga-based Facility
Read more -
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
Read more -
ZEJULA – a new maintenance treatment option for Canadians living with ovarian cancer – now available in Canada
ZEJULA – a new maintenance treatment option for Canadians living with ovarian cancer – now available in Canada
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines and prescribed vaccines
-
Research & development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products.
-
Careers
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
